

Myobloc® (rimabotulinumtoxinB)



When requesting Myobloc® (rimabotulinumtoxinB), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines for the covered indications.

FDA-approved indication

- Myobloc® (rimabotulinumtoxinB) is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain.

Coverage Guidelines

The individual must meet all of the following criteria for approval:

- Failure or tolerance to Botox® (onabotulinumtoxinA)
- No hypersensitivity to any botulinum toxin product or excipients
- No infection at the proposed injection site
- 18 years of age or older

Approval duration: 12 months

Recommended Dosing

Cervical dystonia- 2500 to 5000 units intramuscularly divided among the affected muscles every 12-16 weeks or longer.

References

1. Myobloc®(rimabotulinumtoxinB) [prescribing information]. South San Francisco, CA: Solstice Neurosciences, Inc.: May2010. Accessed July 6, 2018.
2. Myobloc® (rimabotulinumtoxinB). Ln: DRUGDEX System Micromedex. Greenwood Village, CO: Thompson Reuters (Healthcare) Inc. [Updated November 17, 2017; Accessed July 16, 2018]
3. Myobloc® (rimabotulinumtoxinB). In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. [Updated February 27.2018; Accessed July 16, 2018].
4. Simpson, DN et al. Practice guideline update summary. Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology, Neurology. 2016; 86(19):1818-1826.